Investment House LLC Sells 3,996 Shares of Charles River Laboratories International, Inc. $CRL

Investment House LLC lessened its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 12.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 27,417 shares of the medical research company’s stock after selling 3,996 shares during the period. Investment House LLC owned 0.06% of Charles River Laboratories International worth $4,290,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in CRL. Allspring Global Investments Holdings LLC lifted its holdings in Charles River Laboratories International by 29.1% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock valued at $353,750,000 after purchasing an additional 516,521 shares during the last quarter. Ariel Investments LLC raised its position in shares of Charles River Laboratories International by 28.6% in the second quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company’s stock valued at $214,751,000 after purchasing an additional 314,572 shares during the period. Invesco Ltd. lifted its stake in shares of Charles River Laboratories International by 11.6% during the 2nd quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company’s stock valued at $187,712,000 after buying an additional 128,785 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of Charles River Laboratories International by 29.2% during the 2nd quarter. Bank of America Corp DE now owns 1,026,013 shares of the medical research company’s stock valued at $155,677,000 after buying an additional 232,020 shares in the last quarter. Finally, Sei Investments Co. boosted its holdings in Charles River Laboratories International by 5.9% in the 2nd quarter. Sei Investments Co. now owns 714,688 shares of the medical research company’s stock worth $108,440,000 after buying an additional 39,959 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $219.77 on Friday. The stock has a market cap of $10.82 billion, a P/E ratio of -140.88, a PEG ratio of 6.56 and a beta of 1.61. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64. The business’s 50-day moving average price is $196.95 and its two-hundred day moving average price is $176.41. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $228.88.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 5th. The medical research company reported $2.43 EPS for the quarter, topping the consensus estimate of $2.32 by $0.11. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.Charles River Laboratories International’s revenue was down .5% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.59 earnings per share. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on CRL. Bank of America raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 target price on the stock in a report on Monday, December 15th. Morgan Stanley set a $185.00 price objective on Charles River Laboratories International in a research note on Monday, December 1st. Barclays raised their target price on Charles River Laboratories International from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a research report on Wednesday. Finally, Evercore ISI raised their price objective on shares of Charles River Laboratories International from $250.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, January 13th. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $209.46.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.